west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "转移" 581 results
  • Correlation between Immunohistochemistry and Pathology for Lung Cancer Lymphatic Metastasis

    Objective To analyze and screen the risk factors of both immunohistochemistry and pathology for lung cancer lymphatic metastasis, and to build a mathematical model for preliminary evaluation. Methods By conducting retrospective studies, the information of lung cancer patients in the General Hospital of Air Force from 2009 to 2011 were collected. Both single and multiple unconditional logistic regression analyses were applied to screen total 27 possible factors for lymphatic metastasis. After the factors with statistical significance were selected, the relevant mathematical model was built and then evaluated by means of receiver operating characteristic (ROC) analysis. Results A total of 216 patients were included. The single analyses on 27 possible factors showed significant differences in the following 10 factors: pathological grade (P=0.00), age (P=0.00), tumor types (P=0.01), nm23 (P=0.00), GSTII (P=0.01), TTF1 (P=0.01), MRP (P=0.01), CK14 (P=0.02), CD56 (P=0.02), and EGFR (P=0.03). The multiple factors unconditional logistic regression analyses on those 10 risk factors screened 4 relevant factors as follows: pathological grade (OR=2.34), age (OR=1.02), nm23 (OR=1.66), and EGFR (OR=1.47). Then a mathematical diagnostic model was established based on those 4 identified risk factors, and the result of ROC analysis showed it could improve the diagnostic sensitivity and specificity compared with the single factor mathematical diagnostic model. Conclusion Pathological grade, age, nm23, and EGFR are related with lung cancer lymphatic metastasis, and all of them are the risk factors which have higher adjuvant diagnostic value for lung cancer lymphatic metastasis.

    Release date: Export PDF Favorites Scan
  • Expression of MTA1 and VEGF-C in Esophageal Squamous Cell Carcinoma and Relationship between Them and Lymphangiogenesis

    ObjectiveTo investigate the expression of tumor metastasis associated genes-1 (MTA1) and vascular endothelial growth factor-C (VEGF-C) in esophageal squamous cell carcinoma (ESCC) and the relationship between them and lymphangiogenesis. MethodA total of 107 patients who received excision for ESCC in the Cardiothoracic Surgery Department of Suining Central Hospital from March 2013 through January 2014 were enrolled. And the paraffinembedded esophageal tissues in 56 healthy persons were collected. The expression of MTA1 and VEGF-C in ESCC was detected using the immunohistochemical method. And D2-40 was used to label the micro-lymphatic endothelial cells of the tumor tissues while the micro-lymphatic vessel density (LVD) was counted. Meanwhile, a statistical analysis was performed for the relationship between MTA1 with VEGF-C and clinical pathological parameters. ResultsThe expression rates of MTA1 protein and VEGF-C protein in ESCC (50.4% and 58.8%, respectively) were higher than those in normal esophageal tissues with a statistical difference (P<0.05). Besides, their high expression rates in stage T3/T4 ESCC and lymph node metastasis group were significantly higher than those in stage T1/T2 ESCC and metastasisfree group, with statistical differences (P<0.05). The high expression rates of MTA1 and VEGF-C protein in ESCC with different TNM stages were compared using Kruskal-Wallis test with statistical differences (P<0.05). Moreover, a positive correlation existed in the expression level between MTA1 protein and VEGF-C protein of ESCC (Spearman coefficient r=0.512, P=0.000). And LVD of the high expression group for MTA1 protein and VEGF-C protein was statistically different from that of the low expression group (P<0.05). ConclusionThe expression of MTA1 is positively correlated with the expression of VEGF-C in ESCC. And they may co-promote lymphangiogenesis and lymphatic metastasis in ESCC. Therefore, both can be used as the laboratory indicators to determine the prognosis of ESCC.

    Release date: Export PDF Favorites Scan
  • Evidence-Based Treatment for a Lung Cancer Patient with Spinal Metastasis

    Objective To establish the evidence-based treatment strategy for an advanced lung cancer case with spinal metastasis, regarding the patient’s condition and treatment expectations. Methods According to PICO principles, questions in the patient’s treatment were converted into a search strategy. The literature searching was performed in several databases. In accordance with the five evidence grading standards in evidence-based medicine, the best clinical evidence was interpreted to guide the treatment decisions. Results A total of 148 papers were detected and screened, of which 4 systematic reviews or meta-analyses were included finally. Four issues that patients concerned, including restoring spinal cord function (walking and sphincter function), local pain control, long-term survival, and treatment complications, were all supported by grade-1 evidence. The patient finally chose surgical decompression, which was of a higher complication risk, but better possibility of restoring nerve function, significant pain relief, and improved long-term survival. The patient obtained fully recovery and regained walking function after surgery. Conclusion The evidence-based treatment is able to provide reasonable treatment options for lung cancer patients with spinal metastasis. Decompression surgery for patients with walking dysfunction should be carried out as soon as possible, in order to early restore spinal marrow function, relieve pain and improve long-term survival. But both doctors and patients should fully acquaint themselves with the higher risk of surgical complications.

    Release date: Export PDF Favorites Scan
  • Zoledronic Acid Combined with Radiotherapy for Bone Metastases of Malignant Tumor: A Meta-Analysis

    Objective To systematically evaluate the effectiveness and safety of zoledronic acid combined with radiotherapy in treating bone metastasis of malignant tumor. Methods Such databases as PubMed, EMbase, The Cochrane Library (Issue 10, 2012), CBM, CNKI, VIP and WanFang Data were searched to collect randomized clinical trials (RCTs) on bone metastasis of malignant tumor from inception to October, 2012. References of included studies were also retrieved. Two reviewers independently screened studies according to exclusion and inclusion criteria, extracted data, and assessed the methodological quality. Then, meta-analysis was performed using RevMan 5.1 software. Results Twenty nine trials were included involving 2 021 patients. The results of meta-analysis showed that, compared with the radiotherapy alone group, zoledronic acid combined with radiotherapy improved the effectiveness rate of pain relieving at the end of treatment (OR=3.08, 95%CI 2.30 to 4.12, Plt;0.000 01), the effectiveness rate of pain relieving two weeks after treatment (OR=3.39, 95%CI 2.52 to 4.56, Plt;0.000 01), the quality of life (OR=2.74, 95%CI 1.66 to 4.52, Plt;0.000 01) and the ability of movement (OR=2.96, 95%CI 2.16 to 4.05, Plt;0.000 01). Zoledronic acid combined with radiotherapy also reduced the incidence of new bone metastasis (OR=0.21, 95%CI 0.10 to 0.45, Plt;0.000 1) and the incidence rate of bone-related events (OR=0.17, 95%CI 0.03 to 0.92, P=0.04). The adverse reactions of zoledronic acid combined with radiotherapy such as fever (OR=11.92, 95%CI 6.31 to 22.48, Plt;0.000 01) and hypocalcaemia (OR=8.82, 95%CI 1.61 to 48.36, P=0.01), significantly increased. Conclusion Compared with radiotherapy alone, zoledronic acid combined with radiotherapy can relieve bone metastatic pain, effectively enhance patients’ ability of movement, improve quality of life, and decrease new bone metastasis and the occurrence of bone-related events.

    Release date: Export PDF Favorites Scan
  • 唑来膦酸治疗恶性肿瘤骨转移患者不良反应的护理

    目的 总结对恶性肿瘤骨转移患者应用唑来膦酸不良反应的护理经验,旨在为临床护理提供指导。 方法 对2011年6月-12月28例恶性肿瘤骨转移患者使用唑来膦酸治疗后所产生的发热、骨关节疼痛、消化道反应、低钙性抽搐、骨坏死及心动过缓等不良反应予以对症护理。 结果 治疗中部分患者出现不良反应:发热6例(21.4%),骨关节疼痛4例(14.3%),胃肠道反应4例(14.3% ),低钙性抽搐2例(7.1%),经对症治疗及护理均予缓解。 结论 唑来膦酸治疗恶性肿瘤骨转移过程中出现的相关并发症,只要采取积极对症的治疗护理措施均可控制。

    Release date:2021-06-23 07:35 Export PDF Favorites Scan
  • 外阴皮肤转移性腺癌一例

    Release date: Export PDF Favorites Scan
  • 恶性脊髓压迫症的治疗策略

    【摘要】转移性硬膜外脊髓压迫(metastatic epidural spinal cord compression,MESCC),也称恶性脊髓压迫,是恶性肿瘤最严重的并发症之一。临床上主要表现为背痛,肌力下降,感觉改变,严重者会出现行走能力的丧失和括约肌功能障碍。新的诊断方法和治疗手段的出现,为MESCC的治疗带来了更多的希望,也提出了更多的挑战。

    Release date:2016-08-26 02:21 Export PDF Favorites Scan
  • Surgical Resection and Reconstruction for Metastatic Spinal Tumors

    目的:探讨脊柱转移瘤患者的手术切除与脊柱稳定性重建的适应证与效果。方法:2003年4月至2008年4月,收治了脊柱转移癌患者32例。肿瘤转移部位:胸椎转移22例,腰椎转移7例,颈椎转移3例。男性13例,女性19例。出现神经系统受损者27例,其中完全瘫痪者7例,不完全瘫痪者20例。全组患者均做了椎体切除、内固定术或后路椎板切除、椎管减压内固定术或前后路联合行360°脊椎切除固定一期重建脊柱稳定性。观察术后局部疼痛缓解,神经功能恢复及脊柱稳定性情况。结果:随访时间为6~60个月,32例患者中,30例术后痛疼得到缓解。27例有神经功能损害的患者中,25例术后麻痹症状改善。3例完全瘫痪的患者中,2例在减压术后ASIA分级提高了1~2个等级。术后影像学提示脊柱序列和椎间高度恢复。术后存活1年以上的患者22例,约占患者总数的69%。结论:外科切除与重建治疗转移癌所致椎体塌陷或不稳定造成严重的神经损害或机械性脊柱痛疼的外科疗效肯定,能够增加脊椎稳定性,提高生存质量。

    Release date:2016-08-26 03:57 Export PDF Favorites Scan
  • KAI1 Gene Expressions in Human Lung Cancer Cell Lines with Different Metastatic Potential

    目的:探讨人肺癌细胞转移潜能与KAI1基因表达的关系。方法:应用real-time RTPCR技术检测不同转移潜能的人肺癌细胞株和正常人成纤维细胞株MRC-5中KAI1基因mRNA的表达水平及差异。结果:人肺癌细胞株中KAI1基因mRNA表达水平均显著低于正常肺成纤维细胞株MRC-5;不同转移潜能人大细胞肺癌细胞株中KAI1基因mRNA表达水平有明显差异。结论:KAI1基因表达降低与人肺癌细胞的转移潜能高低有关!

    Release date:2016-08-26 03:57 Export PDF Favorites Scan
  • Efficacy Evaluation of Press Sore Prevention in Patients with Metastasis Tumor Bone

    目的:为肿瘤骨转移患者压疮预防的方法进行总结评价以达到对临床肿瘤压疮进行指导。方法:采用改良后的诺顿评估表(信度0.80,效度0.84)作为压疮易患患者评估工具。评估内容包括患者年龄、身体状况、意识、活动能力、运动受限情况、疼痛、皮肤情况、大小便失禁、饮食、进食能力、口腔情况、牙齿及患者血色素、蛋白等资料。评估时间从患者入院开始,对30例肿瘤全身多处骨转移患者进行评估,有预见性、计划性,针对性及个体化对患者制订护理计划及措施,并督促实施,对效果进行评价分析。结果:≤25分高危险性患者(难以避免)发生率50%,26~29分中度危险性患者(可避免)发生率0,≥30分低危险性患者发生率14.2%。效果评价:压疮预防评估对肿瘤骨转移患者压疮的预防是有效的,压疮评估有助于规范护理行为和护理管理;通过分析找出护理过程中的薄弱环节,以利于指导临床工作。

    Release date:2016-08-26 03:57 Export PDF Favorites Scan
59 pages Previous 1 2 3 ... 59 Next

Format

Content